<DOC>
	<DOCNO>NCT02999711</DOCNO>
	<brief_summary>Purpose study ass safety tolerability multiple ascend subcutaneous dos REGN3500 moderate asthmatic .</brief_summary>
	<brief_title>Study Safety , Tolerability , Pharmacokinetics Multiple Ascending Doses REGN3500 Adults With Moderate Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Male female age 18 55 year , Body mass index ( BMI ) 18 32 kg/m2 A diagnosis moderate asthma ( accord GINA 2015 ) period least 2 year prior screen . Patient must use stable medium daily dose level inhaled corticosteroid ( ICS ) define GINA guideline , ie , total daily dose ICS &gt; 400 μg ≤800 μg/day budesonide equivalent least 1 month prior screen study A prebronchodilator forced expiratory volume first sec ( FEV1 ) ≥60 % ≤85 % predicted normal value screen predose randomization A document positive response reversibility test screening , define improvement FEV1 ≥12 % ≥200 mL baseline 400 μg salbutamol Pmdi Willing able comply clinic visit studyrelated procedure Provide sign informed consent . Clinically significant abnormal CBC , clinical chemistry , urine analysis screening . Treatment investigational drug within 8 week within 5 halflives ( know ) , whichever longer , prior screen . History lifethreatening asthma Occurrence asthma exacerbation respiratory tract infection within 4 week prior screen . Diagnosis airway/pulmonary disease Chronic Obstructive Pulmonary Disease ( COPD ) define Global Initiative Chronic Obstructive Lung Disease ( GOLD ) guideline ( GINA 2015 ) ; lung disease ( eg , emphysema , idiopathic pulmonary fibrosis , ChurgStrauss syndrome , allergic bronchopulmonary aspergillosis cystic fibrosis , bronchiectasis alpha1 antitrypsin deficiency restrictive lung disease ) . Chronic acute infection require treatment systemic antibiotic , antiviral , antifungal within 1 month prior screen . Use oral antibiotics/antiinfectives within 2 week prior screen . Known sensitivity doxycycline tetracycline , component investigational product formulation . Recent ( within previous 2 month ) bacterial , protozoal , viral , parasite infection . History tuberculosis systemic fungal disease Patients treat monoclonal antibody base therapy ( antiIgE , antiIL5 ) , biologic therapy immunotherapy ( subcutaneous immunotherapy [ SCIT ] , sublingual immunotherapy [ SLIT ] , oral immunotherapy [ OIT ] ) previous 12 week prior screen study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>